%0 Journal Article %A Bateman, Eric D. %A Price, David B. %A Wang, Hao-Chien %A Khattab, Adel %A Schonffeldt, Patricia %A Catanzariti, Angelina %A van der Valk, Ralf J. P. %A Beekman, Maarten J.H.I. %T Short-acting β₂-激动剂处方与哮喘的不良临床结局相关:为了获得短期β2激动剂(SABA)在哮喘患者中的处方和相关哮喘相关临床结局的全球视角，研究人员对SABA的临床疗效进行了评估。我们评估了五大洲24个国家的初级卫生数据。方法SABINA III是一项横断面研究，在研究访问(初级或专科护理)中使用电子病例报告表格，记录处方药物、非处方(OTC) SABA购买和过去12个月哮喘患者(≥12岁)的临床结果。在≥1个SABA处方的患者中，采用多变量回归模型分析SABA与哮喘症状控制和严重加重的相关性。研究招募了8351名患者(n=6872名专家;N =1440，初级保健)，76.5%的患者有中度至重度哮喘，45.4%的患者在过去12个月内经历过≥1次严重发作。38%的患者处方≥3个SABA罐;18.0%的人购买了非处方SABA，其中76.8%的人同时获得了SABA处方。3-5、6-9、10-12和≥13 SABA的处方(与1-2相比)与哮喘受控或部分受控的比值越来越低相关(比值比[95% CI]分别为0.64[0.53-0.78]、0.49[0.39-0.61]、0.42[0.34-0.51]和0.33 [0.25-0.45];n=4597)和更高的严重加重率(发生率比[95% CI]: 1.40 [1.24-1.58]; 1.52 [1.33–1.74]; 1.78 [1.57–2.02]; 1.92 [1.61–2.29], respectively; n=4612).Conclusions This study indicates an association between high SABA prescriptions and poor clinical outcomes across a broad range of countries, healthcare settings and asthma severities, providing support for initiatives to improve asthma morbidity by reducing SABA over-reliance.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: EDB is a member of the Science Committee and Board of GINA and reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Orion, Regeneron Pharmaceuticals and Sanofi Genzyme.Conflict of interest: DBP has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron, Sanofi Genzyme, Teva Pharmaceuticals and Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline (GSK), Mylan, Mundipharma, Novartis, Pfizer, Teva and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron, Respiratory Effectiveness Group, Sanofi Genzyme, Teva, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kyorin, Mylan, Mundipharma, Novartis, Regeneron, Sanofi Genzyme and Teva; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis and Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GSK.Conflict of interest: H-CW has nothing to disclose.Conflict of interest: AK has nothing to disclose.Conflict of interest: PS reports lectures on medical education and inclusion as a researcher on clinical study protocols funded by AstraZeneca, GSK, Teva, ITF Labomed, Boehringer Ingelheim and Sanofi Genzyme.Conflict of interest: AC is employee of AstraZeneca.Conflict of interest: RJPvdV is employee of AstraZeneca and has shares in GSK and shares and options in AstraZeneca.Conflict of interest: MJHIB was an employee of AstraZeneca at the time the study was conducted and has shares in AstraZeneca. %U //www.qdcxjkg.com/content/erj/early/2021/09/09/13993003.01402-2021.full.pdf